Propofol Exerts Anti-Hepatocellular Carcinoma by Microvesicle-Mediated Transfer of Mir-142-3p from Macrophage to Cancer Cells

Jian Zhang,Wei-feng Shan,Te-te Jin,Guo-qing Wu,Xiao-xing Xiong,Hai-yan Jin,Sheng-mei Zhu

DOI: https://doi.org/10.1186/s12967-014-0279-x

IF: 8.44

2014-01-01

Journal of Translational Medicine

Abstract:OBJECTIVE:We previously confirmed that propofol directly inhibited the viability, proliferation, and invasiveness of hepatocellular carcinoma cells in vitro. In this study, we investigated the mechanism underlying the anti-HCC effects of propofol.METHODS:In vivo antitumor activity was investigated in tumor-bearing mice following an intraperitoneal injection of propofol, with or without clodrolip. The co-culture system was used to verify that miR-142-3p was transported from macrophages to HCC cells. A miR-142-3p inhibitor was used to down-regulate the expression of miR-142-3p.RESULTS:Propofol drastically inhibited tumor growth in tomor-bearing mice through macrophage activation, and stimulated tumor-associated macrophages (TAMs) to secrete microvesicles (MVs), which delivered miR-142-3p to HCC cells, resulting in the inhibition of HCC cell invasion. In addition, MVs collected from the plasma of the tumor-bearing mice injected with propofol suppressed tumor growth. More importantly, down-regulation of the expression miR-142-3p reversed the effect of propofol on HCC cell migration.CONCLUSIONS:This study reveals a novel role for propofol in the inhibition of HCC through MV-mediated transfer of miR-142-3p from macrophages to cancer cells in vivo.